Polymer Delivery Systems for Long-Acting Antiretroviral Drugs.
Mohammad Ullah NayanSudipta PanjaAshrafi SultanaLubaba A ZamanLalitkumar K VoraBrady SillmanHoward E GendelmanBenson EdagwaPublished in: Pharmaceutics (2024)
The success of long-acting (LA) drug delivery systems (DDSs) is linked to their biocompatible polymers. These are used for extended therapeutic release. For treatment or prevention of human immune deficiency virus type one (HIV-1) infection, LA DDSs hold promise for improved regimen adherence and reduced toxicities. Current examples include Cabenuva, Apretude, and Sunlenca. Each is safe and effective. Alternative promising DDSs include implants, prodrugs, vaginal rings, and microarray patches. Each can further meet patients' needs. We posit that the physicochemical properties of the formulation chemical design can optimize drug release profiles. We posit that the strategic design of LA DDS polymers will further improve controlled drug release to simplify dosing schedules and improve regimen adherence.
Keyphrases
- drug release
- drug delivery
- end stage renal disease
- endothelial cells
- newly diagnosed
- ejection fraction
- chronic kidney disease
- hiv infected
- human immunodeficiency virus
- prognostic factors
- antiretroviral therapy
- peritoneal dialysis
- big data
- type diabetes
- hiv aids
- patient reported outcomes
- metabolic syndrome
- hiv infected patients
- hepatitis c virus
- replacement therapy
- combination therapy
- glycemic control
- artificial intelligence
- machine learning
- deep learning
- adipose tissue
- weight loss
- soft tissue
- patient reported